Genevant

The University of Texas’s Medical Branch in Galveston, Texas, strives to enable students to become leading practitioners, teachers, and investigators in the healthcare field.  Academics at the UT Medical Branch are available through four different schools, each with its own specialization:    * School of Medicine    * School of Nursing    * School of Health Professions    * Graduate School of Biomedical Sciences  In addition to programs in these schools, the Medical Branch also offers three combined MD-PhD degrees: Biomedical Sciences, Medical Humanities, and Biomedical Engineering.  Graduate students may enroll in their choice of more than 25 residencies and 35 subspecialty fellowship programs, gaining real world experience for their future career in professional environments. Some of these programs are:    * Aerospace Medicine    * Anesthesiology    * Dermatology    * Internal Medicine    * Obstetrics and Gynecology    * Ophthalmology    * Radiation Oncology    * And many more  On-campus housing is not offered, but the school provides information of nearby housing options.  Financial aid is available to eligible students through federal work study, scholarships, and student loans.

Delivering solutions through RNA therapeutics.

Genevant Sciences is a leading nucleic acid delivery company that specializes in developing lipid nanoparticle (LNP) technology for RNA-based medicines. The company was founded in 2018 as a joint venture between Arbutus Biopharma Corporation and Roivant Sciences. Genevant's LNP platform enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. The company's scientists have pioneered LNP delivery of nucleic acids for over 20 years, and its technology is behind the first and only approved systemic RNA-LNP product, patisiran. Genevant's LNP technology has been studied across more than a dozen discrete product candidates and is designed to deliver RNA payloads safely and effectively to specific tissues, overcoming a major obstacle in unlocking the broad therapeutic potential of RNA-based medicines.

Gritstone bio and Genevant Sciences Announce Option and License Agreement

Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha

Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A

With mRNA Technology, Vaccines and Therapeutics Stay on Message

Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency

Moderna sued over Covid-19 vaccine-related patents

Roivant launches new subsidiary in Basel to develop therapeutics for genetic diseases

RNA Therapeutics

Editas strengthens in vivo gene therapy strategy with $238M Genevant pact, looks for reni-cel partner

The University of Texas Medical Branch

Profectus Biosciences

Vanderbilt University

Mapp Biopharmaceutical

Genevant Sciences is a leading nucleic acid delivery company that specializes in developing lipid nanoparticle (LNP) technology for RNA-based medicines. The company was founded in 2018 as a joint venture between Arbutus Biopharma Corporation and Roivant Sciences. Genevant's LNP platform enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. The company's scientists have pioneered LNP delivery of nucleic acids for over 20 years, and its technology is behind the first and only approved systemic RNA-LNP product, patisiran. Genevant's LNP technology has been studied across more than a dozen discrete product candidates and is designed to deliver RNA payloads safely and effectively to specific tissues, overcoming a major obstacle in unlocking the broad therapeutic potential of RNA-based medicines.
Key customers and partnerships
Genevant has entered into several collaborations and licensing agreements with pharmaceutical and biotechnology companies. In August 2023, Genevant signed an agreement with Gritstone bio for the use of its LNP technology in developing self-amplifying RNA vaccines for infectious diseases. In March 2023, the company partnered with Korro Bio to develop an RNA editing therapeutic for Alpha-1 Antitrypsin Deficiency. In November 2023, Genevant announced a collaboration with Novo Nordisk to develop an in vivo gene editing treatment for hemophilia A using its LNP technology. The company also has partnerships with Takeda for liver disease medicines, BioNTech for cancer targets and some rare diseases, and Gritstone for a self-amplifying RNA Covid-19 vaccine program.

<div>
 
 PYC Therapeutics is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. The company utilizes a proprietary drug delivery platform based on Cell-Penetrating Peptides (CPPs) to enhance the potency of precision medicines within the RNA therapeutic class. PYC's technology aims to overcome the delivery challenges associated with traditional RNA therapeutics, allowing for more effective treatment of genetic ailments.
 
 
 
 
 PYC's lead drug candidate, VP-001, is designed to treat Retinitis Pigmentosa type 11 (RP11), a blinding eye disease that begins in childhood. VP-001 targets the U4/U6 small nuclear ribonucleoprotein (PRPF31) gene and is administered through intravitreal injection. In August 2023, the US Food and Drug Administration (FDA) granted Fast Track designation to VP-001, potentially expediting its development and review process. In May 2024, PYC reported encouraging first clinical data for VP-001 in RP11 patients.
 
 
 
 
 The company's pipeline includes other preclinical programs for Inherited Retinal Diseases and Central Nervous System disorders. In May 2024, PYC received orphan drug designation from the FDA for PYC-001, a drug candidate targeting autosomal dominant optic atrophy (ADOA). PYC is also developing VP-002 and exploring multiple candidates for eye and CNS indications.
 
 
 
 
 In January 2024, PYC announced plans to collaborate with Google Cloud to develop new precision medicines. This project aims to utilize machine learning models, merging AlphaFold and its successors, to predict ideal peptide sequences and structures for delivering precision medicine cargoes to cells in the human body.
 
 
 
 
 For the half-year ended December 31, 2023, PYC reported revenue of AUD 9.12 million, up from AUD 3.49 million in the previous year. The company's net loss for the period was AUD 15.09 million. As of March 31, 2024, PYC had a pro-forma cash balance of approximately AUD 84 million, providing runway into the second half of 2025 for its ongoing clinical trials.
 
</div>

PYC Therapeutics

Flamingo Therapeutics is a biotechnology company specializing in RNA-targeted therapies for oncology. Founded in 2019, the company focuses on developing treatments for difficult-to-treat cancers using state-of-the-art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo's lead program is danvatirsen, an antisense oligonucleotide (ASO) that selectively targets STAT3 and has shown clinical activity in two Phase II studies. Danvatirsen binds to STAT3 mRNA, inhibiting translation of the transcript, resulting in reduced tumor cell growth and activation of anti-tumor immunity. Flamingo initiated the PEMDA-HN Phase II trial evaluating danvatirsen in combination with pembrolizumab for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The company is also advancing FTX-001, its most advanced long non-coding RNA (LncRNA) program targeting MALAT-1, through readiness for Phase 1 trials in solid tumors. Flamingo's proprietary discovery engine, FLAME (Flamingo LncRNA Antisense Mining Engine), addresses lncRNAs, a large and untapped class of disease-causing targets within the "dark matter" of the human genome. In March 2023, Flamingo merged with Dynacure to create a leading RNA therapeutics company focused on clinical oncology, combining their pipelines and expertise.
Key customers and partnerships
Flamingo Therapeutics has established strategic alliances and partnerships to advance its RNA-targeted therapies. The company has an expanded alliance with Ionis Pharmaceuticals, a world leader in RNA-targeted antisense oligonucleotide (ASO) therapeutics. This partnership, announced in September 2021, combines three clinical-stage programs from Ionis with Flamingo's novel lncRNA discovery engine and preclinical lncRNA program. The alliance leverages Flamingo's expertise in oncology and long non-coding RNAs with Ionis' proficiency in RNA-targeted drug discovery and development. Additionally, Flamingo collaborates with academic partners at VIB, KU Leuven, Ghent University, and the University of Michigan, whose pioneering work in non-coding RNA genes in cancer contributed to the company's foundation. In June 2023, Flamingo received a EUR 1.7 million research grant from Flanders Innovation & Entrepreneurship (VLAIO) to advance its RNA-targeting oncology portfolio, further validating its approach in creating a pipeline of programs targeting undruggable transcription factors and non-coding RNA.

Flamingo Therapeutics

Korro Bio is a biotechnology company focused on developing RNA editing therapeutics for both rare and common diseases. Founded in 2018, the company is headquartered in Cambridge, Massachusetts. Korro's proprietary platform, called OPERA (Oligonucleotide Promoted Editing of RNA), leverages the body's natural ADAR (adenosine deaminase acting on RNA) system to make precise edits to RNA transcripts. This approach allows for the correction of genetic mutations without permanently altering DNA, potentially offering a safer alternative to traditional gene editing techniques.
The company's lead program targets alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. Korro's AATD candidate aims to repair inherited mutations and restore production of normal functional alpha-1 antitrypsin (A1AT) protein in the liver. preclinical studies have demonstrated an increase of normal A1AT protein to 85% of total protein in circulation. Korro plans to submit a regulatory filing to initiate clinical trials for this candidate in the second half of 2024.
Beyond AATD, Korro is developing RNA editing therapies for conditions such as Parkinson's disease, severe alcoholic hepatitis, amyotrophic lateral sclerosis (ALS), subsets of pain, and cardiometabolic diseases. The company's initial focus is on liver-targeted therapies, with plans to expand into central nervous system indications and other tissue types.
In July 2023, Korro Bio announced plans to go public through a reverse merger with Frequency Therapeutics. The combined company will operate under the Korro Bio name and trade on the Nasdaq stock exchange under the ticker symbol KRRO. This transaction, along with a concurrent USD 117 million financing, is expected to provide Korro with approximately USD 170 million in cash upon closing, which is anticipated to fund operations into 2026.

Korro Bio

Halo-Bio is a biopharmaceutical company focused on developing innovative therapies. The company has a licensing agreement with Tekmira Pharmaceuticals related to certain lipid nanoparticle (LNP) technologies.

Halo-Bio RNAi Therapeutics

Oncotelic Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA therapeutics and small molecule drugs for cancer and infectious diseases. The company's lead drug candidate is OT-101, a first-in-class RNA therapeutic designed to target TGF-β2, a protein that suppresses immune cell response and contributes to tumor growth in cancer tissues. OT-101 has demonstrated notable single-agent activity in clinical trials for relapsed/refractory cancer patients, with overall survival increasing in a dose-dependent manner at levels of 140mg/m2 and higher.
Oncotelic is currently conducting a Phase 2 billion/Phase 3 clinical trial called STOP-PC to evaluate OT-101 in combination with mFOLFIRINOX compared to mFOLFIRINOX alone for patients with advanced and unresectable or metastatic pancreatic cancer. The company believes this trial could deliver a decisive win against pancreatic cancer based on previous data showing improved survival in patients with low TGF-β2 expression treated with irinotecan.
In addition to its oncology pipeline, Oncotelic has explored OT-101's potential against SARS-CoV-2, completing a Phase 2 trial for Covid-19 in November 2021 with positive top line data for safety and efficacy. The company has also acquired AL-101 for intranasal delivery of apomorphine, which it intends to develop for conditions including Parkinson's Disease, erectile dysfunction, and female sexual disorders.

Oncotelic

Companies developing treatments using molecules like antisense oligonucleotides (ASOs) and phosphorodiamidate morpholino oligomers (PMOs). These molecules target specific genes to treat genetic diseases by either silencing or modifying gene expression.

Companies using RNA interference (RNAi) to target and silence specific genes involved in diseases for treating various conditions by blocking harmful gene activity.

Companies involved in altering RNA molecules to modify gene expression or correct genetic defects. This can include substitutions, insertions, or deletions of nucleotides, leading to alterations in the RNA sequence and the regulation of RNA molecules to control gene expression or cellular functions.

Companies focused on other RNA-based therapies using approaches such as tRNA, circRNA, lncRNA, and saRNA to develop treatments targeting specific RNA molecules to regulate gene expression.

RNA-based developments form a foundation for precision medicine.

RNA plays essential roles in gene expression, regulation, and protein synthesis, making it a fundamental focus in genomic research and understanding genetic mechanisms.

Reinventing gene therapies with next-generation technologies

Human Gene Editing

PROMINENT_CATEGORY

<div>
 
 
 Gene-editing firm Editas Medicine and lipid nanoparticle (LNP) technology company Genevant Sciences have formed a partnership to develop gene-editing therapies. Editas will acquire a nonexclusive license to future products created under this cooperation, and Genevant is eligible for payments and royalties amounting to $283 million on forthcoming sales.
 
The joint venture will combine Editas's CRISPR/Cas12a gene editing system with Genevant's LNP technology to develop in vivo gene editing medicines with unspecified targets. It could potentially pave the way for novel treatments in genetic up-regulation.
 
</div>

Genevant

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless